The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SNDX | -28.75% | -15.49% | -3.31% | +13% |
| S&P | +16.9% | +95.99% | +14.39% | +241% |
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
The company announced results from an early-stage clinical study.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $37.96M | 984.5% |
| Gross Profit | $36.68M | 0.0% |
| Gross Margin | 96.63% | 0.0% |
| Market Cap | $805.83M | -53.8% |
| Market Cap / Employee | $2.98M | 0.0% |
| Employees | 270 | 46.7% |
| Net Income | -$71.85M | -5.6% |
| EBITDA | -$69.35M | 6.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $108.64M | 3.1% |
| Accounts Receivable | $31.77M | 0.0% |
| Inventory | 17.7 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $325.74M | 237665.0% |
| Short Term Debt | $19.79M | 1892.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -62.43% | -4.3% |
| Return On Invested Capital | -28.73% | 24.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$87.80M | -22.5% |
| Operating Free Cash Flow | -$87.80M | -22.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.50 | 3.09 | 3.65 | 3.75 | 5.64% |
| Price to Sales | 102.79 | 47.90 | 24.21 | 10.34 | -97.93% |
| Price to Tangible Book Value | 4.50 | 3.09 | 3.65 | 3.75 | 5.64% |
| Enterprise Value to EBITDA | -14.02 | -9.41 | -10.68 | -10.08 | -43.63% |
| Return on Equity | -81.9% | -75.7% | -93.7% | -113.2% | 78.86% |
| Total Debt | $0.85M | $345.74M | $345.63M | $345.52M | 30477.26% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
